Loading...
•
Jun 30, 2021
Allakos Q2 2021 Earnings Report
Allakos reported financial results for the second quarter ended June 30, 2021.
Key Takeaways
Allakos reported a net loss of $57.2 million for the second quarter of 2021, compared to $39.3 million in the same period in 2020. The company ended the quarter with $559.7 million in cash, cash equivalents and marketable securities.
Presented new data at Digestive Disease Week (DDW) 2021 suggesting EG/EoD is significantly underdiagnosed.
Completed patient enrollment in Phase 3 EG/EoD and Phase 2/3 EoE clinical trials of lirentelimab (AK002).
Topline data from Phase 3 study of lirentelimab in patients with EG/EoD expected in the fourth quarter of 2021.
Topline data from Phase 2/3 study of lirentelimab in patients with EoE expected in the fourth quarter of 2021.
Forward Guidance
Allakos anticipates topline data from Phase 3 EG/EoD and Phase 2/3 EoE clinical trials in Q4 2021 and initiation of Phase 2/3 study of subcutaneous lirentelimab in patients with EG and/or EoD in the second half of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...